In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Kelly to share insights from her career as a solo practitioner in veterinary oncology. Dr. Kelly reflects on the realities of running a private practice and the unique challenges and opportunities it presents. She highlights her open-minded approach to integrating a wide range of therapeutics and diagnostic tools, always with the goal of providing the best possible patient care. Throughout the conversation, Dr. Kelly also discusses how adaptability, clinical curiosity, and a patient-centered mindset have guided her work and shaped her contributions to the field.

📝Transcripts are available at https://www.imprimedicine.com/podcast.

To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/ppp

Music Credit: Hazy by Beat Mekanik

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. David Vail, renowned veterinary oncologist, professor at the University of Wisconsin–Madison, and co-editor of the widely used Small Animal Clinical Oncology textbook. Dr. Vail reflects on the evolution of veterinary oncology over the past four decades, sharing pivotal developments such as the introduction of Tanovea and the wide-reaching impact of Cerenia. He explores the rise of comparative oncology and the increasingly bidirectional collaboration between veterinary and human medicine. The discussion highlights cutting-edge advances in immunotherapy and how combination therapies and naturally occurring canine cancer trials are shaping human clinical research. Tune in for a thoughtful look at the past, present, and future of oncology through the lens of a true pioneer.

📝Transcripts are available at https://www.imprimedicine.com/podcast.

To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/ppp

Music Credit: Hazy by Beat Mekanik

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Steve Dow, professor of immunology at Colorado State University and Director of the Center for Immune and Regenerative Medicine. Dr. Dow shares insights from his groundbreaking work on myeloid-targeted immunotherapies and the innovative use of repurposed, FDA-approved drugs like losartan, palladia, and propranolol in treating canine cancers such as osteosarcoma and brain tumors. He also discusses the development of tumor vaccines, promising adjuvant trial results, and the critical role dogs play as translational models in advancing human cancer therapies. The episode highlights the future potential of bispecific antibodies and CAR-T cell therapies in both veterinary and human oncology.

📝Transcripts are available at https://www.imprimedicine.com/podcast.

To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/ppp

Music Credit: Hazy by Beat Mekanik